Polen Capital acquired 13.5 Million Abbott Laboratories shares worth $1.43 Billion. That's 3.28% of their equity portfolio (12th largest holding). The first Abbott Laboratories trade was made in Q3 2013. Since then Polen Capital bought shares sixteen more times and sold shares on thirteen occasions. The stake costed the investor $1.21 Billion, netting the investor a gain of 18% so far.
Aristotle Capital Management LLC decreased its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 12.1% in the second quarter, according to the comp...
The AM Reporter, 4 months ago… 69.62%. Abbott Laboratories Company Profile (Free Report) Abbott Laboratories , together with … in four segments: Established Pharmaceutical Products, Diag...
EIN News Pharmaceuticals, 6 months ago… 24th. Wolfe Research upgraded Abbott Laboratories from an “underperform” rating … on ABT Abbott Laboratories Company Profile (Free Report) Abbott Laborator...
EIN News Pharmaceuticals, 7 months agoOn CNBC’s " Halftime Report Final Trades ," Bryn Talkington of Requisite Capital Management named Innovator U.S. Equity Power Buffer ETF October (NYSE: POCT ...
Benzinga, 7 months ago